Method of treating non-alcoholic steatohepatitis
AssigneeMedicNova, Inc.
InventorKazuko Matsuda
Life of this patent
Estimating the term…
Abstract
A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic steatohepatitis (NASH) and/or reducing one or more of hepatic fibrosis, lobular inflammation, and hepatocellular ballooning.
Claims30
A method of treating a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (I):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of treating a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (IB):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof.
A method of reducing liver inflammation in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (I):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of reducing liver inflammation in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (IB):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof.
A method of reducing hepatic fibrosis in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (I):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of reducing hepatic fibrosis in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (IB):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof.
A method of reducing damage to liver cells in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (I):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X1 and X2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X1 and X2 are not simultaneously oxygen atom.
A method of reducing damage to liver cells in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (IB):
- or an ester thereof, or a pharmaceutically acceptable salt of each thereof.
Dependencies are inferred from the claim text.